Price Chart
Key Statistics
Market Cap(EOD)6.71B
Enterprise Value6.65B
P/E Ratio (TTM)-17.05
P/B Ratio (TTM)9.39
P/S Ratio (TTM)21.14
Earnings Yield (TTM)-5.87%
ROE (TTM)-50.54%
ROIC (TTM)-51.26%
Net Profit Margin (TTM)N/A
Dividend Yield (TTM)N/A
Payout Ratio (TTM)N/A
Debt/Equity (TTM)0.17
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.